5 July 2107
Intelligent Fingerprinting strengthens R&D team
- Appoints Alan Pang – formerly Alere Toxicology’s Head of Technical Manufacturing and Assay Development – as R&D Programme Manager
- “Fingerprint-based testing represents the next major breakthrough for drug screening technology, and I want to be part of it” – Alan Pang
Intelligent Fingerprinting, the Cambridge-based company developing the world’s first portable fingerprint-based drug screening system, has appointed Alan Pang as its Programme Manager for R&D as the company moves towards commercialization. Alan Pang joins Intelligent Fingerprinting from drug and alcohol testing provider Alere Toxicology, where he was Head of Technical Manufacturing and Assay Development.
Alan Pang brings over 15 years’ testing experience to Intelligent Fingerprinting, having been closely involved with the development and roll-out of Alere Toxicology’s portfolio of oral fluid and urine screening technologies – both visual and reader based. His appointment is part of the continued expansion of Intelligent Fingerprinting’s R&D and manufacturing facilities, where he will play a key role in supporting the introduction of the company’s unique fingerprint-based Drug Screening System later this summer.
“Throughout my career I’ve tracked all the key innovations in drug screening technology and it has become clear that fingerprint-based testing – which works by analyzing the sweat from a fingerprint sample – has the potential to disrupt the industry in a major way,” commented Alan Pang. “The fact that the technology is portable, rapid, non-invasive and easy-to-use makes it particularly attractive across a range of important market sectors, so I was obviously keen to get involved. I’m delighted to be joining Intelligent Fingerprinting, and look forward to helping establish our fingerprint-based diagnostic technology as the number one choice for use at the point-of-care.”
Alan Pang began his career in the forensic toxicology and drug screening industry as a Production Scientist for Cozart in 2001. He then became an R&D Scientist with Concateno before assuming the role of Lead R&D Scientist at Alere Toxicology in 2012. Alan holds a degree in biotechnology from Oxford Brookes University.
Dr. Jerry Walker, Intelligent Fingerprinting’s CEO, added: “Alan Pang’s appointment is a pivotal addition to the Intelligent Fingerprinting R&D team as we move towards commercialization. He brings in-depth experience of the drug screening challenges facing organizations across our target sectors, as well as a real understanding of how our portable Intelligent Fingerprinting system can play an important role in supporting both current and future drug screening requirements.”
To learn more about how non-invasive drug screening works view our latest video demonstration:
For media information contact Cheryl Billson at Comma
Email: email@example.com Tel: +44 (0)7791 720460
Notes to Editors:
About Intelligent Fingerprinting
Intelligent Fingerprinting’s unique fingerprint-based portable Drug Screening System is set to revolutionize the way drug screening is carried out across a range of sectors. The distinctive Intelligent Fingerprinting technology, which works by analyzing the sweat from a fingerprint sample, enables non-invasive, cost-effective screening for multiple drug groups in less than 10 minutes, currently amphetamines, cannabis, cocaine and opiates.
Intelligent Fingerprinting has attracted worldwide interest in its technology from a wide range of drug-screening markets including the criminal justice arena, drug rehabilitation centers, prisons and occupational health services. The technique has potential for many other uses including healthcare diagnostics and homeland security applications.
The company’s ground-breaking technology detects drug use by analyzing chemicals, known as metabolites, contained in the minute traces of sweat found in a fingerprint. (Metabolites are chemicals produced by the body as a result of normal metabolic processes.) The Intelligent Fingerprinting Drug Screening System looks for the presence of specific drugs or drug metabolites in the test subject’s fingerprint sweat sample and, if detected, identifies which drugs have been consumed.
Since 2012 Intelligent Fingerprinting has raised £11.23m in funding from a consortium of private UK and US-based investors, as well as government funding for pilot studies within the UK’s National Health Service and coroners’ services.
Founded in 2007, Intelligent Fingerprinting is a spin-out company from the University of East Anglia (UEA). The company is based in Cambridge, England and currently employs 26 people.
Follow us on Twitter @iFingerprinting